Cresilon's TRAUMAGEL: A Game-Changer in Emergency Medicine
August 16, 2024, 10:32 pm
Location: United States, New York
Employees: 11-50
Founded date: 2010
Total raised: $77M
In the world of emergency medicine, seconds can mean the difference between life and death. Cresilon Inc., a Brooklyn-based biotechnology company, has taken a monumental step forward with the FDA clearance of TRAUMAGEL, a revolutionary hemostatic gel designed to control moderate to severe bleeding almost instantaneously. This innovation is not just a product; it’s a lifeline.
TRAUMAGEL is the first of its kind, utilizing a proprietary plant-based hydrogel technology. Imagine a quick-drying sponge that stops blood flow in its tracks. This gel is applied directly to a wound, halting life-threatening hemorrhages in mere seconds. In a landscape where traditional methods can be cumbersome and time-consuming, TRAUMAGEL emerges as a beacon of hope.
The urgency of this innovation cannot be overstated. Every three minutes, someone dies from an injury, with 40% of these fatalities attributed to major hemorrhages. The clock is ticking. Up to 60% of these deaths occur within the first three hours post-injury. TRAUMAGEL aims to change this grim statistic.
Current hemostatic agents often require preparation and can be challenging to apply. They are not one-size-fits-all solutions. TRAUMAGEL, however, comes in a pre-filled syringe, ready to use. No fuss, no delays. Just apply and watch the bleeding stop. This ease of use is crucial for emergency medical services (EMS), military personnel, and healthcare providers who face traumatic wounds daily.
Cresilon’s mission is clear: to save lives. The company plans to strategically launch TRAUMAGEL in late 2024, targeting not only civilian markets but also military and government health agencies. The U.S. military, in particular, stands to benefit significantly. Soldiers in combat zones often face severe injuries where every second counts. TRAUMAGEL could be the difference between life and death on the battlefield.
This FDA clearance is Cresilon's second significant achievement. The first was for Cresilon Hemostatic Gel (CHG), approved in June 2023 for minor wounds. With TRAUMAGEL, Cresilon is expanding its reach into more critical areas of trauma care. The company operates from a state-of-the-art biomanufacturing facility in Brooklyn, a hub of innovation and technology.
The potential applications of TRAUMAGEL extend beyond just external bleeding. Recent studies in collaboration with the U.S. Defense Department's Walter Reed Army Institute of Research explore its use in mitigating life-threatening brain hemorrhages. This research could revolutionize treatment protocols for traumatic brain injuries (TBI), offering neuroprotection in prehospital settings.
Cresilon’s plant-based technology is a game-changer. Traditional hemostatic agents often rely on synthetic materials that may not be as effective or safe. In contrast, TRAUMAGEL’s natural composition aligns with a growing trend towards biocompatible medical solutions. This approach not only enhances safety but also addresses concerns about the long-term effects of synthetic materials in the body.
The market for hemostatic agents is competitive, yet TRAUMAGEL stands out. Its rapid action, ease of use, and versatility across various types of bleeding set it apart from existing products. In emergency situations, where time is of the essence, TRAUMAGEL offers a solution that is both effective and efficient.
Cresilon’s commitment to innovation has not gone unnoticed. The company was recently named the top medical device innovator by Fast Company in its annual list of the World’s Most Innovative Companies for 2024. This recognition underscores the importance of their work and the potential impact of TRAUMAGEL on the medical field.
As the launch date approaches, anticipation builds. Medical professionals are eager to integrate TRAUMAGEL into their practices. Training programs will likely accompany the rollout, ensuring that users are well-versed in its application. The goal is clear: to equip first responders and healthcare providers with the best tools available to save lives.
In conclusion, TRAUMAGEL is more than just a product; it’s a revolutionary advancement in emergency medicine. With its ability to stop severe bleeding in seconds, it has the potential to transform trauma care. Cresilon is not just making a product; they are crafting a future where lives are saved, and injuries are managed more effectively. As we stand on the brink of this new era in medical technology, one thing is certain: TRAUMAGEL is poised to make waves in the world of emergency response. The countdown to its launch has begun, and the medical community is ready to embrace this game-changing innovation.
TRAUMAGEL is the first of its kind, utilizing a proprietary plant-based hydrogel technology. Imagine a quick-drying sponge that stops blood flow in its tracks. This gel is applied directly to a wound, halting life-threatening hemorrhages in mere seconds. In a landscape where traditional methods can be cumbersome and time-consuming, TRAUMAGEL emerges as a beacon of hope.
The urgency of this innovation cannot be overstated. Every three minutes, someone dies from an injury, with 40% of these fatalities attributed to major hemorrhages. The clock is ticking. Up to 60% of these deaths occur within the first three hours post-injury. TRAUMAGEL aims to change this grim statistic.
Current hemostatic agents often require preparation and can be challenging to apply. They are not one-size-fits-all solutions. TRAUMAGEL, however, comes in a pre-filled syringe, ready to use. No fuss, no delays. Just apply and watch the bleeding stop. This ease of use is crucial for emergency medical services (EMS), military personnel, and healthcare providers who face traumatic wounds daily.
Cresilon’s mission is clear: to save lives. The company plans to strategically launch TRAUMAGEL in late 2024, targeting not only civilian markets but also military and government health agencies. The U.S. military, in particular, stands to benefit significantly. Soldiers in combat zones often face severe injuries where every second counts. TRAUMAGEL could be the difference between life and death on the battlefield.
This FDA clearance is Cresilon's second significant achievement. The first was for Cresilon Hemostatic Gel (CHG), approved in June 2023 for minor wounds. With TRAUMAGEL, Cresilon is expanding its reach into more critical areas of trauma care. The company operates from a state-of-the-art biomanufacturing facility in Brooklyn, a hub of innovation and technology.
The potential applications of TRAUMAGEL extend beyond just external bleeding. Recent studies in collaboration with the U.S. Defense Department's Walter Reed Army Institute of Research explore its use in mitigating life-threatening brain hemorrhages. This research could revolutionize treatment protocols for traumatic brain injuries (TBI), offering neuroprotection in prehospital settings.
Cresilon’s plant-based technology is a game-changer. Traditional hemostatic agents often rely on synthetic materials that may not be as effective or safe. In contrast, TRAUMAGEL’s natural composition aligns with a growing trend towards biocompatible medical solutions. This approach not only enhances safety but also addresses concerns about the long-term effects of synthetic materials in the body.
The market for hemostatic agents is competitive, yet TRAUMAGEL stands out. Its rapid action, ease of use, and versatility across various types of bleeding set it apart from existing products. In emergency situations, where time is of the essence, TRAUMAGEL offers a solution that is both effective and efficient.
Cresilon’s commitment to innovation has not gone unnoticed. The company was recently named the top medical device innovator by Fast Company in its annual list of the World’s Most Innovative Companies for 2024. This recognition underscores the importance of their work and the potential impact of TRAUMAGEL on the medical field.
As the launch date approaches, anticipation builds. Medical professionals are eager to integrate TRAUMAGEL into their practices. Training programs will likely accompany the rollout, ensuring that users are well-versed in its application. The goal is clear: to equip first responders and healthcare providers with the best tools available to save lives.
In conclusion, TRAUMAGEL is more than just a product; it’s a revolutionary advancement in emergency medicine. With its ability to stop severe bleeding in seconds, it has the potential to transform trauma care. Cresilon is not just making a product; they are crafting a future where lives are saved, and injuries are managed more effectively. As we stand on the brink of this new era in medical technology, one thing is certain: TRAUMAGEL is poised to make waves in the world of emergency response. The countdown to its launch has begun, and the medical community is ready to embrace this game-changing innovation.